Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II

Savitz, Sean I. ; Chopp, Michael ; Deans, Robert ; Carmichael, S. T. ; Phinney, Donald ; Wechsler, Larry ; Aronowski, Jaraslow ; Bednar, Martin ; Boltze, Johannes and Borlongan, Cesar , et al. (2011) In Stroke 42(3). p.825-829
Abstract

Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy... (More)

Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy of cell therapies for stroke. Any successful development of a cell product will need to take into consideration several factors, including the preclinical safety and efficacy profile, cell characterization, delivery route, in vivo biodistribution, and mechanism of action. In 2010, a second meeting called STEPS 2 was held to bring together clinical and basic science researchers with industry, regulatory, and National Institutes of Health representatives. At this meeting, participants identified critical gaps in knowledge and research areas that require further studies, updated prior guidelines, and drafted new recommendations to create a framework to guide future investigations in cell-based therapies for stroke.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cell therapy, guidelines, stem cells, stroke
in
Stroke
volume
42
issue
3
pages
5 pages
publisher
American Heart Association
external identifiers
  • scopus:79952072156
ISSN
0039-2499
DOI
10.1161/STROKEAHA.110.601914
language
English
LU publication?
yes
id
caf3ac72-8f69-4465-90ce-1275667d7eec
date added to LUP
2019-09-03 16:56:51
date last changed
2021-09-29 02:23:36
@article{caf3ac72-8f69-4465-90ce-1275667d7eec,
  abstract     = {<p>Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy of cell therapies for stroke. Any successful development of a cell product will need to take into consideration several factors, including the preclinical safety and efficacy profile, cell characterization, delivery route, in vivo biodistribution, and mechanism of action. In 2010, a second meeting called STEPS 2 was held to bring together clinical and basic science researchers with industry, regulatory, and National Institutes of Health representatives. At this meeting, participants identified critical gaps in knowledge and research areas that require further studies, updated prior guidelines, and drafted new recommendations to create a framework to guide future investigations in cell-based therapies for stroke.</p>},
  author       = {Savitz, Sean I. and Chopp, Michael and Deans, Robert and Carmichael, S. T. and Phinney, Donald and Wechsler, Larry and Aronowski, Jaraslow and Bednar, Martin and Boltze, Johannes and Borlongan, Cesar and Chase, Thomas and Corbett, Dale and Cox, Charles S. and Cramer, Steven and Fischkoff, Steven and Frank, Joseph and Greenberg, David and Hess, David and Hong, Klaudyne and Koga, Minako and Jones, Theresa and Keating, Armand and Kokaia, Zaal and Mays, Robert and Mora, Keita and Pittenger, Mark and Sanberg, Paul and Schallert, Tim and Sinden, John and Snyder, Evan and Steinberg, Gary and Victor, Steven and Willing, Alison and Yankee, Ernest and Yavagal, Dileep},
  issn         = {0039-2499},
  language     = {eng},
  month        = {03},
  number       = {3},
  pages        = {825--829},
  publisher    = {American Heart Association},
  series       = {Stroke},
  title        = {Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II},
  url          = {http://dx.doi.org/10.1161/STROKEAHA.110.601914},
  doi          = {10.1161/STROKEAHA.110.601914},
  volume       = {42},
  year         = {2011},
}